HSC 835

Drug Profile

HSC 835

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; Spanlecortemlocel

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Stem cell therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies

Most Recent Events

  • 01 Oct 2016 Novartis completes a phase I/II trial in Haematological malignancies in USA (NCT01474681)
  • 16 Mar 2016 Novartis plans a phase I/II trial for Mucopolysaccharidosis-I, Metachromatic leukodystrophy, Globoid cell leukodystrophy and Cerebral adrenoleukodystropy (In infants, In children, In adolescents, In adults) in USA (Parenteral) (NCT02715505)
  • 23 Apr 2015 Phase-II clinical trials in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top